COST SHOULDN’T STOP PATIENTS
FROM BEING PREPARED
ELIGIBLE PATIENTS MAY PAY AS LITTLE AS $0* FOR ZIMHI
STOP PATIENTS
FROM BEING
PREPARED
MAY PAY AS LITTLE AS
$0* FOR ZIMHI
The Prescription Savings Program helps make it easier for your commercially insured patients to get a ZIMHI prescription. Patients will be able to print out their program savings card or bookmark it on their smartphone. When they provide their pharmacy with the ID number on the card, they will get their ZIMHI prescription discount.
To healthcare professionals: Depending upon the participating pharmacy, the ZIMHI discount may be provided by Change Healthcare or Relay Health. Discounts will be automatically applied; physical card is not necessary.
The Prescription Savings Program helps make it easier for your commercially insured patients to get a ZIMHI prescription. Patients will be able to print out their program savings card or bookmark it on their smartphone. When they provide their pharmacy with the ID number on the card, they will get their ZIMHI prescription discount.
To healthcare professionals: Depending upon the participating pharmacy, the ZIMHI discount may be provided by Change Healthcare or Relay Health. Discounts will be automatically applied; physical card is not necessary.
EVERY MOMENT MATTERS
The strength to pull them back from an overdose
Actor portrayal
FAST ABSORPTION WITH ZIMHI
WHY A HIGH NALOXONE DOSE?
HELPFUL TIPS FOR TALKING TO
PATIENTS ABOUT ZIMHI
EVERY
MOMENT
MATTERS
The strength to pull them
back from an overdose
Actor portrayal
FAST ABSORPTION WITH ZIMHI
WHY A HIGH NALOXONE DOSE?
HELPFUL TIPS FOR TALKING TO
PATIENTS ABOUT ZIMHI
EVERY
MOMENT
MATTERS
The strength to pull them
back from an overdose
FAST ABSORPTION WITH ZIMHI
WHY A HIGH NALOXONE DOSE?
HELPFUL TIPS FOR TALKING TO
PATIENTS ABOUT ZIMHI
In an opioid overdose emergency,
ZIMHI MAY MAKE ALL
THE DIFFERENCE
REQUEST A TRAINING DEVICE
In an opioid overdose emergency,
ZIMHI MAY
MAKE ALL THE
DIFFERENCE
REQUEST A TRAINING DEVICE
In an opioid overdose emergency,
ZIMHI MAY
MAKE ALL THE
DIFFERENCE
REQUEST A TRAINING DEVICE
*Patients whose prescriptions are paid for in part or in whole by Medicare, Medicaid, or any similar federal or state healthcare program, are not eligible for savings or rebates according to federal and state law. Patients must visit a participating pharmacy for savings or rebates on their ZIMHI prescriptions. Maximum benefits may apply. The actual savings and out-of-pocket costs for ZIMHI will vary according to refill quantity, personal healthcare insurance coverage, and adherence to FDA dosing guidelines. Please review Terms and Conditions to learn more.
INDICATION
ZIMHI is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI is not a substitute for emergency medical care.
IMPORTANT SAFETY INFORMATION
As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.
Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine may be incomplete. Repeat doses of ZIMHI may be required.
Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of signs and symptoms of opioid withdrawal.
Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
After use, the ZIMHI needle is exposed until the safety guard is deployed. A needlestick injury could occur during use in emergency situations. In the event of accidental needlestick injury, medical attention should be sought.
The following adverse reactions were most commonly observed in ZIMHI clinical studies: dizziness, lightheadedness, and elevated bilirubin.
To report SUSPECTED ADVERSE REACTIONS, contact Adamis Pharmaceuticals Corporation at 1-800-230-3935 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch
IMPORTANT SAFETY INFORMATION and INDICATION for ZIMHI™
As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.
Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine may be incomplete. Repeat doses of ZIMHI may be required.
IMPORTANT SAFETY INFORMATION and INDICATION for ZIMHI™
As the duration of action of naloxone hydrochloride is shorter than many opioids, keep the patient under continued surveillance and administer repeated doses of naloxone using a new ZIMHI device, as necessary, while awaiting emergency medical assistance.
